| Symbol | OGEN |
|---|---|
| Name | ORAGENICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 9015 TOWN CENTER PARKWAY, LAKEWOOD RANCH, FL 34202 |
| Telephone | 8132867900 |
| Fax | — |
| — | |
| Website | https://www.oragenics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001174940 |
| Description | Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus. Additional info from NASDAQ: |
New Form DEFA14A - ORAGENICS INC <b>Filed:</b> 2026-05-20 <b>AccNo:</b> 0001493152-26-024605 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - ORAGENICS INC <b>Filed:</b> 2026-05-20 <b>AccNo:</b> 0001493152-26-024602 <b>Size:</b> 1 MB
Read moreOragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
Read moreOragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
Read moreOragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
Read more(85% Positive) ORAGENICS INC (OGEN) Announces Enrollment Update for people Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreOragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06870240 | A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate… | Phase2 | Mild Traumatic Brain Injury, Concussion | Not_Yet_Recruiting | 2025-06-01 | 2026-03-31 | ClinicalTrials.gov |
| NCT03234465 | Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placeb… | Phase2 | Oral Mucositis | Terminated | 2017-07-18 | 2020-07-13 | ClinicalTrials.gov |
| NCT01520974 | Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (… | Na | Oral Health | Unknown | 2012-01-01 | — | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo tablet | Other | Approved | Oral Health | UNKNOWN | NCT01520974 |
| ProBiora3 mints | Other | Approved | Oral Health | UNKNOWN | NCT01520974 |
| Placebo | Other | Phase PHASE2 | Oral Mucositis | TERMINATED | NCT03234465 |
| AG013 | Other | Phase PHASE2 | Oral Mucositis | TERMINATED | NCT03234465 |
| Neurosteroid enantiomer | Other | Phase PHASE2 | Mild Traumatic Brain Injury, Concussion | NOT_YET_RECRUITING | NCT06870240 |
| Neurosteroid enantiomer | DRUG | Phase PHASE2 | Mild Traumatic Brain Injury, Concussion | NOT_YET_RECRUITING | NCT06870240 |
| Placebo | OTHER | Phase PHASE2 | Oral Mucositis | TERMINATED | NCT03234465 |
| AG013 | BIOLOGICAL | Phase PHASE2 | Oral Mucositis | TERMINATED | NCT03234465 |
| Placebo tablet | OTHER | Approved | Oral Health | UNKNOWN | NCT01520974 |
| ProBiora3 mints | OTHER | Approved | Oral Health | UNKNOWN | NCT01520974 |